Side effects of metoclopramide as an antiemetic in childhood cancer chemotherapy

Terrin, Bruce N.; McWilliams, Nancy B.; Maurer, Harold M.

doi:10.1016/s0022-3476(84)80613-7

Cited by 62 publications

(14 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…chlorpromazine, metoclopramide Carefully designed studies involving the use of ondansetron in paediatric patients should be performed to confirm whether the results of safety and efficacy studies in adults may or may not be extended to children. For example, dystonic reactions and other side effects (agitation, headache, dysarthria, grimacing) associated with metoclopramide are more common in children than adults (Terrin, McWilliams & Maurer 1984). Thus it is not appropriate to consider the use of metoclopramide in children as safe as its use in adults.…”

Section: Discussionmentioning

confidence: 99%

Rapid intravenous administration of ondansetron or metoclopramide is not associated with cardiovascular compromise in children

Rose¹,

McCloskey

1995

Pediatric Anesthesia

View full text Add to dashboard Cite

This double blinded, placebo controlled, randomized, and prospective study investigated the effect of the rapid intravenous administration of ondansetron 0.15 mg.kg-1 or metoclopramide 0.25 mg.kg-1 on the heart rate, haemoglobin saturation, systolic blood pressure, and diastolic blood pressure in 45 ASA PS I-II children between two and 16 years of age prior to elective tonsillectomy. The study groups were not significantly different with respect to age, weight, or gender. We were unable to detect a change in heart rate, systolic or diastolic blood pressure, or haemoglobin saturation following the rapid administration of ondansetron or metoclopramide. We conclude intravenous ondansetron or metoclopramide (for the prevention of postoperative vomiting) are not associated with cardiovascular instability when administered rapidly to healthy children prior to elective surgery.

show abstract

Section: Discussionmentioning

confidence: 99%

Rapid intravenous administration of ondansetron or metoclopramide is not associated with cardiovascular compromise in children

Rose¹,

McCloskey

1995

Pediatric Anesthesia

View full text Add to dashboard Cite

show abstract

“…Serious side effects associated with Meto are estimated to occurr in approximately 1 % of patients [23][24][25]. Extrapyramidal move ments (presumably due to central CNS dopa mine antagonism), torticollis, neck pain, and oculogyric crisis have been reported as rare complications of this commonly used drug.…”

Section: Discussionmentioning

confidence: 99%

Metoclopramide Promotes Enteral Feeding in Preterm Infants with Feeding Intolerance

Meadow¹,

Bui²,

Strates³

et al. 1989

Dev Pharmacol Ther

View full text Add to dashboard Cite

We hypothesized that the feeding difficulties experienced by premature infants are related to immature peristaltic activity and that a bowel accelerant might promote feeding in prematures. We administered metoclopramide (Meto) to 14 infants admitted to the Intensive Care Nursery at The University of Chicago between January 1, 1984, and January 1, 1987. Each infant had failed enteral feeding on at least two separate occasions. At the time of initiation of Meto, the group of infants tolerated only 11.7 ± (SEM) 3.6 cm^3/kg/day enterally. Feeding tolerance improved steadily after Meto was initiated, and by 29 days the infants tolerated 134 ± 12.6 cm^3/kg/day enterally. The average slope of the post-Meto feeding regression lines was +4.21 ± 0.94 cm^3/kg/day/day, significantly greater than -0.67 ± 0.59 cm^3/kg/day/day pre-Meto. The percentage of feedings followed by significant gastric residual volumes was 33.1 ± 4.6% pre-Meto, compared to 6.9 ± 2.5% post-Meto. No child receiving Meto developed any extrapyramidal neurologic symptoms, worsening of hepatic function, or necrotizing enterocolitis. Meto may have a role in the treatment of premature infants with enteral feeding intolerance.

show abstract

“…After the demonstration that high-dose intravenous metoclopramide was efficacious in the prevention of cisplatin-induced emesis in adult patients [15], dose-finding studies were carried out to identify the optimal intravenous (i.v.) every 4-8 h for up 48 h was evaluated [37]. In one of these, 26 children were randomised to one of four different doses of metoclopramide (0.25, 0.5, 1.0 and 2.0 mg/kg), administered every 3 h for five doses starting 30 min before chemotherapy [13].…”

Section: Receptor Antagonistsmentioning

confidence: 99%

Optimal selection of antiemetics in children receiving cancer chemotherapy

Roila¹,

Aapro

Stewart

1998

Supportive Care in Cancer

View full text Add to dashboard Cite

Only a few studies have been carried out specifically on the prevention of nausea and vomiting in children receiving chemotherapy. In these patients older antiemetic drugs such as metoclopramide and phenothiazines had moderate efficacy and induced significant side effects, especially marked sedation and extrapyramidal reactions. In comparative trials the 5-HT3 receptor antagonists have shown better efficacy and tolerability than chlorpromazine or metoclopramide combined with dexamethasone. The combination of a 5-HT3 receptor antagonist plus dexamethasone is superior to a 5-HT3 receptor antagonist alone and should be the standard antiemetic prophylaxis in all paediatric patients receiving highly or moderately emetogenic chemotherapy. The optimal dose and scheduling of these antiemetic drugs need to be studied, as well as the antiemetic efficacy, in the prevention of chemotherapy-induced delayed and anticipatory emesis in children.

show abstract

Side effects of metoclopramide as an antiemetic in childhood cancer chemotherapy

Cited by 62 publications

References 7 publications

Rapid intravenous administration of ondansetron or metoclopramide is not associated with cardiovascular compromise in children

Rapid intravenous administration of ondansetron or metoclopramide is not associated with cardiovascular compromise in children

Metoclopramide Promotes Enteral Feeding in Preterm Infants with Feeding Intolerance

Optimal selection of antiemetics in children receiving cancer chemotherapy

Contact Info

Product

Resources

About